FDA Warning: Equipment Design & Biofilm Risks
Austin Chuang • April 10, 2026
How ignored Performance Qualification (PQ) failures and systemic dead legs in pharmaceutical water systems led to an FDA Warning Letter.
Equipment Design Flaws Lead to FDA Warning Letter
Executive Summary
During a recent US site inspection of a French pharmaceutical manufacturer, the FDA identified severe structural and operational deficiencies in a process system used for OTC drugs (identified as a water system). The system suffered from critical design flaws, including dead legs and stagnant locations, which fostered biofilm development and repeated microbial failures. The agency escalated the matter because the manufacturer continued utilizing the system for production despite long-standing deviations from USP specifications during and after Performance Qualification (PQ).
The FDA emphasized the presence of "dead legs" and stagnant zones within the piping. These structural areas prevent proper fluid velocity and sanitization, inherently enabling the development of harmful biofilms.
The qualification report was improperly approved even though extensive sampling during Performance Qualification (PQ) indicated that the majority of samples failed to meet USP specifications.
Continuous monitoring over two years showed gram-negative bacteria, including Pseudomonas aeruginosa and Serratia marcescens , serving as clear indicators of systemic biofilm proliferation.
The company documented long-standing deviations without an appropriate response. The FDA demanded a comprehensive technical assessment covering temperature, materials, slopes, fittings, and flow velocities.
Ensure Audit-Ready Hygienic Systems with PE
Persimmon Engineering specializes in the architectural design, assessment, and compliant qualification of pharmaceutical water and process systems. We can help you identify dead legs, resolve bio-burden risks, and build foolproof requalification strategies before the FDA steps in.
Request a Technical AssessmentOriginal Source Content
25.03.2026
Deficiencies in Equipment Design lead to Warning Letter
During the inspection of a US site belonging to a French pharmaceutical manufacturer, the FDA identified serious deficiencies, including in a process system for the manufacture of OTC drugs.
The deficiencies relate to both the equipment design and its qualification.
Although the FDA only refers to a system for supplying a medium used in production in its warning letter, it can be assumed from context that this very likely refers to the manufacturer's water system.
In the FDA's opinion, the system is neither structurally nor operationally capable of reliably maintaining the required chemical and microbiological quality parameters.
Extensive sampling was already carried out during performance qualification (PQ), with the majority of samples failing to meet the relevant USP specifications.
Despite these repeated negative results, the qualification report was approved.
In the following two years, the monitoring data continued to show almost continuous deviations from the USP requirements.
Nevertheless the system continued to be used in the manufacture of drugs.
The FDA is particularly critical of the equipment's inadequate design.
The process system has numerous design flaws, including several so-called dead legs and stagnant locations.
According to the FDA, such areas are critical because they can lead to the development of biofilm.
Furthermore, the company was already aware of the existence of these design flaws.
Microbiological testing confirmed this problem. Gram-negative bacteria, including Pseudomonas aeruginosa and Serratia marcescens , which are considered typical waterborne germs and indicate the presence of biofilms, were repeatedly detected in samples.
In its statement, the company announced that it would fundamentally overhaul the process system.
Among other things, it planned to remove dead legs, install additional system components, and requalify the system.
However, the FDA considers this response to be inadequate, as the company had repeatedly documented deviations over a long period of time without responding appropriately.
The manufacturer also stated that it would temporarily stop using the medium from this system for drug manufacturing and instead use externally sourced material until the system has been completely refurbished.
The FDA is requesting a comprehensive technical assessment of the system design and operational controls.
This assessment should identify all design and operational weaknesses. In particular, fundamental system parameters that are critical to hygienic design and safe operation should be reviewed.
These include, among other things, the temperature in the system, the materials used, the slope of the piping, identified dead legs and other stagnant locations, unsanitary fittings or connections, and the flow velocity within the system.
In addition, maintenance and monitoring procedures are to be revised and the system re-qualified.
Furthermore, the agency has requested a detailed risk assessment regarding the possible impact on drug batches that have already been manufactured and are currently available on the US market.
The detailed warning letter can be found on the FDA website.
出處：https://www.gmp-compliance.org/gmp-news/deficiencies-in-equipment-design-lead-to-warning-letter
Primary Keywords (Short-Tail): FDA Warning Letter, Hygienic Design, Water Systems, Biofilm, Equipment Qualification.
Targeted Phrases (Long-Tail): Dead legs in pharmaceutical water systems, Performance Qualification (PQ) failures, FDA cGMP equipment design compliance, Resolving stagnant piping locations, Waterborne microbiological contamination.
Hashtags: #PharmaCompliance #FDAWarningLetter #HygienicDesign #Validation #PersimmonEngineering.